Biomarkers in anal cancerQuantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer

Background and purposeTo explore the integration of imaging and molecular data for response prediction to chemoradiotherapy (CRT) for rectal cancer.Material and methodsEighty-five rectal cancer patients underwent preoperative CRT. 18F-FDG PET/CT and diffusion-weighted imaging (DWI) were acquired before (TP1) and during CRT (TP2) and prior to surgery (TP3). Inflammatory cytokines and gene expression were analysed. Tumour response was defined as ypT0-1N0. Multivariate models were built combining the obtained parameters. Final models were calculated on the data combination with the highest AUC.ResultsTwenty-two patients (26%) achieved ypT0-1N0 response. 18F-FDG PET/CT had worse predictive performance than DWI and T2-volumetry (AUC 0.61 ± 0.04, 0.72 ± 0.03, and 0.72 ± 0.02, respectively). Combining all imaging parameters increased the AUC to 0.81 ± 0.03. Adding cytokines or gene expression did not improve the AUC (AUC of 0.72 ± 0.06 and 0.79 ± 0.04 respectively). Final models combining 18F-FDG PET/CT, DWI, and T2-weighted volumetry at all TPs and using only TP1 and TP3, allowed ypT0-1N0 prediction with a 75% sensitivity, 94% specificity and PPV of 80%.ConclusionsCombining 18F-FDG PET/CT, DWI, and T2-weighted MRI volumetry obtained before CRT and prior to surgery may help physicians in selecting rectal cancer patients for organ-preservation.